1. Introduction {#s0005}
===============

Obesity increases the risk of insulin resistance and type 2 diabetes mellitus (T2DM) [@bib1]. However, some obese individuals, often referred to as the insulin sensitive (IS) or metabolically healthy obese (MHO), exhibit a lower risk of these diseases than predicted by their obesity [@bib2]. Understanding the mechanisms underlying the protection found in IS obesity could help individuals suffering from pathological obesity. Obesity is characterized by increased size of adipose tissue through hypertrophy and hyperplasia of adipocytes [@bib3]. Preadipocytes, an abundant cell population within the adipose tissue, replenish the adipocyte pool through adipogenesis [@bib4]. Superior adipogenesis of preadipocytes isolated from sub-cutaneous (SC) adipose tissues taken from IS obese individuals compared to insulin resistant (IR) counterparts was recently suggested to play a role in the protection process of IS obesity, which is partially mediated by lower IL-6 secretion and oxidative stress [@bib5], [@bib6]. Obesity-associated oxidative stress leads to elevated reactive oxygen species (ROS) production causing lipid peroxidation within the adipose tissue [@bib7] and accumulation of reactive aldehydes [@bib8], [@bib9]. Elevated 4-hydroxynonenal (4-HNE), a bioactive lipid peroxidation product, leads to progressive impairment of cell structure and function *via* formation of stable 4-hydroxyalkenals with proteins, phospholipids and DNA [@bib10], [@bib11]. Elevation of 4-HNE has been associated with impaired adipogenesis, insulin resistance, atherosclerosis and even obesity of apparently healthy people [@bib6], [@bib12], [@bib13], [@bib14], [@bib15].

Metformin (dimethylbiguanidine), the most widely used drug for the treatment of T2DM [@bib16], [@bib17], is an insulin-sensitizing agent that provides glycemic control, especially in obese individuals [@bib18]. Metformin can reduce adipose tissue size *in vivo* [@bib19] and *in vitro* by inhibiting adipogenesis, decreasing lipogenic gene expression and increasing AMPK activity and glucose intake [@bib20], [@bib21], [@bib22]. Metformin is frequently given to T2DM in combination with insulin [@bib23]. Previous studies have shown that intensive insulin therapy reverses the decrease in adipocyte glucose transport activity in T2DM [@bib24] and counters inflammation by decreasing levels of IL-6 and TNFα [@bib25]. Insulin is commonly used in *in vitro* studies to induce adipogenesis, as it triggers a series of transcription factors that drive differentiation of pre-adipocytes into mature adipocytes including phosphorylation and activation of CREB [@bib26] and PI 3-kinase [@bib27].

Characterization of adipogenesis in the omental (OM) adipose tissues, a depot that is associated with increased metabolic disease risk [@bib28], in IS, IR and T2DM obese individuals remains to be elucidated. Additionally, the effects of metformin on human OM adipogenesis has not been tested, although metformin-mediated glucose uptake by SC and OM adipocytes was previously described [@bib29]. Comparing adipogenesis of OM-derived preadipocytes between IS and IR individuals and the impact of local 4-HNE on this process in primary cultures would provide valuable insights into the potentially protective mechanism associated with the IS group. The aims of the study were to test three hypotheses: 1) adipogenic capacity of OM preadipocyte is impaired in IR and T2DM individuals compared to IS subjects, 2) this impairment is accompanied by elevated 4-HNE accumulation in the adipose tissue that can directly inhibit adipogenesis, and 3) a combination of metformin/insulin treatment can rescue impaired OM adipogenesis.

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

IL-6 and leptin ELISAs were purchased from R&D systems (Abingdon, UK) and Insulin ELISA from Mercodia Diagnostics (Sweden). Diaminobenzidine tetrahydrochloride (DAPI) and LipidTOX™ Green Neutral Lipid were obtained from Life Technologies (Warrington, UK). RT2 Profiler human adipogenesis PCR arrays and cDNA synthesis kits were purchased from SABiosciences-Qiagen, (Hilden, Germany). Other chemicals and reagents were purchased from Sigma (Germany) unless otherwise indicated.

2.2. Cohort {#s0020}
-----------

Patient recruitment criteria were previously published [@bib5]. Briefly, forty consented obese patients (20 females and 20 males, matched for age and BMI) undergoing weight reduction surgery at Hamad Medical Corporation (HMC) (Doha, Qatar) were recruited. Protocols were approved by Institutional Review Boards of HMC and ADLQ (SCH-ADL-070, SCH-JOINT-111). Blood was collected prior to operation and 1--5 g OM adipose tissues biopsies were collected during the surgery. Plasma cholesterol, fasting glucose, Hba1c and liver function enzymes were measured by COBAS INTEGRA (Roche Diagnostics, Basil). IL-6, leptin and insulin were determined using commercially available ELISA. Insulin resistance was computed by homeostatic model assessment (HOMA-IR) [@bib30] using 30th percentile (HOMA-IR=2.4) as a threshold point. Accordingly, subjects were dichotomized into IS (HOMA-IR\<2.4, n=8) and IR (HOMA-IR\>2.4, n=32), including 11 subjects with T2DM (5 on metformin only, 5 on metformin and insulin injection and 1 diet treated).

2.3. Preadipocytes culture and differentiation {#s0025}
----------------------------------------------

Stromal vascular fraction **(**SVF) cells were obtained by collagenase digestion of OM adipose tissues as described previously [@bib31]. Cell pellets were re-suspended in stromal medium containing DMEM-F12 supplemented with 10% FBS and Penicillin/Streptomycin, then maintained at 37 °C with 5% CO~2~ until confluence. To induce differentiation, early passaged SVF-derived preadipocytes (passages 1--3) were grown at 2×10^4^/cm^2^ in stromal medium overnight then incubated in differentiation medium (DMEM-F12, 3% FBS, 33 μM biotin, 17 μM [d]{.smallcaps}-pantothenate, 1 μM dexamethasone, 250 μM of methylisobutylxanthine, 0.1 μM human insulin, 5 μM of PPARγ agonist, rosiglitazone) for 7 days, followed by 12 days in maintenance medium containing same components as differentiation medium omitting methylisobutylxanthine and rosiglitazone [@bib32]. Differentiation potential (adipogenic capacity) was determined as a percentage of lipidtox positive stained cells to total number of stained nuclei (DAPI). For experiments investigating the effect of 4-HNE, metformin, insulin and their various combinations on differentiation, cells were grown as above in the absence or presence of repeated (every 3 days) of 10 µM 4-HNE, 1 mM metformin, 0.1 μM human insulin or their combinations for the entire differentiation and maintenance periods.

2.4. Gene expression studies {#s0030}
----------------------------

RNA was extracted from differentiated OM adipocytes using Trizol following manufacturer\'s instructions. One microgram of RNA was used to synthetize cDNA and gene expression profiling was determined using RT2 Profiler human adipogenesis PCR arrays by assessing mRNA levels of 84 genes, including five \"housekeeping genes\" according to manufacturer\'s protocol. The list of genes included Cyclin D1 (CCND1), Fatty Acid Binding Protein 4 (FABP4), TSC22 Domain Family Member 3 (TSC22D3) and Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Beta (PPARGC1B, also known as PGC1beta). Data were normalized with the internal housekeeping genes and ΔΔCt was calculated using ΔCt from IS as the control group according to manufacturer\'s protocol.

2.5. Measurement of ROS production {#s0035}
----------------------------------

Intracellular ROS levels were assessed using 2′,7′-dichlorofluorescein-diacetate (DCFH-DA, Fluka) probe as described previously [@bib33]. Briefly, cells were incubated with DCFH-DA (10 µM) in the HBSS for 30 min followed by removal of the probe and treatment with 4-HNE (10 µM) in stromal medium containing 3% FBS. The fluorescence intensity (relative fluorescence units, RFU) was measured every hour for 12 h using TECAN Infinite M200 PRO plate reader equipped with gas control mode to maintain 37 °C and 5% CO~2~.

2.6. 4-HNE staining {#s0040}
-------------------

Immunohistochemical analysis of adipose tissues biopsies was performed as previously described [@bib6]. Briefly, formalin-fixed and paraffin-embedded sections made from paraffin blocks were stained with Haematoxylin/Eosin (HE) or with a monoclonal antibody specific for the HNE-histidine epitope in HNE-protein (peptide) conjugates. For the immunohistochemical detection of the HNE-protein adducts the immunoperoxidase technique was used using EnVision kit (Dako, Denmark) as described previously [@bib34]. HNE positivity was estimated using a semi-quantitative method by an experienced pathologist (−0% positive cells, +\<5% positive cells, ++5--25% positive cells, +++25--50% positive cells, ++++\>50% positive cells). The presence of HNE-protein adducts in connective tissue, inflammation and in blood vessels was defined as negative (-) in the absence of the HNE-protein adducts, or as low positive (+, ++) or high positive (+++, ++++) in the presence of the HNE-protein adducts [@bib35].

2.7. Statistical analysis {#s0045}
-------------------------

Comparisons were performed using *t*-test, Wilcoxon--Mann--Whitney and 1-way ANOVA in IBM SPSS statistics 21. Significance was defined as P≤0.05. Power calculations indicated that the present sample size (n=40) had 80% power to detect a minimal difference of 30% in mean differentiation capacity of IS *versus* IR+ type 2 diabetes mellitus with 35% deviation from mean value (sigma) at a level of α=0.05.

3. Results {#s0050}
==========

3.1. Insulin resistance-associated impairment of OM adipogenesis {#s0055}
----------------------------------------------------------------

Forty obese and morbidly obese (BMI=43.6±6.7 kg m^-2^), young (age=35.6±11.9 years) patients were included in this study. General characteristics of the cohort were previously published [@bib5] and shown for the studied group in [Supplementary Table S1](#s0095){ref-type="sec"}. Both metformin monotherapy or metformin and insulin combined therapy exhibited a comparable glycemic control over T2DM patients as indicated by the matching Hba1c levels, despite the non-significant elevation in FPG and insulin levels in the combined treatment group. The metformin and insulin treatment group showed significant reduction in systemic IL-6 levels compared to patients treated with metformin monotherapy ([Table S1](#s0095){ref-type="sec"}).

The adipogenic capacity of SVF-derived preadipocytes was assessed in all participants. Compared to IS individuals, IR and T2DM patients exhibited reduced OM adipogenic capacity by 26.3% (p\<0.01) ([Fig. 1](#f0005){ref-type="fig"}A, B). As the obtained data revealed that the adipogenic capacity was equally reduced in IR and T2DM groups ([Fig. 1](#f0005){ref-type="fig"}B), these two groups were further combined when conducting gene expression comparison in order to increase the power ([Fig. 1](#f0005){ref-type="fig"}C). The reduced adipogenic capacity of IR & T2DM-derived preadipocytes was associated with up-regulation of anti-adipogenic genes CCND1, FABP4 and TSC22D3 and down-regulation of the pro-adipogenic gene PPARGC1B ([Fig. 1](#f0005){ref-type="fig"}C). Interestingly, preadipocytes expanded from T2DM patients who were treated with a combination of metformin and insulin showed greater adipogenic capacity than those treated with metformin monotherapy ([Fig. 1](#f0005){ref-type="fig"}D), as well as the diet-treated individual (4%). The reversing of the adipogenic capacity in the combined treatment group (20.3%), compared to metformin monotherapy group (1.7%) ([Fig. 1](#f0005){ref-type="fig"}D), is still lower than that of the IS group (43.1%, [Fig. 1](#f0005){ref-type="fig"}B), perhaps due to the anti-adipogenic effect of metformin.Fig. 1Comparison of adipogenic capacity of OM preadipocytes isolated from insulin sensitive (IS), insulin resistant (IR) and type 2 diabetes mellitus (T2DM) patients treated with metformin monotherapy or a combination of metformin and insulin. Representative images of differentiated adipocytes by Arrayscan XTI reader showing fluorescently labelled lipid droplets (x200) (A). Differentiation of expanded preadipocytes was assessed by automated scoring of the percentage of lipidtox positive cells (green) to total number of cells (blue) (adipogenic capacity) in IS (n=8), IR (n=21) and T2DM (n=11) (B). Fold change in gene expression of Cyclin D1 (CCND1), Fatty Acid Binding Protein 4 (FABP4), TSC22 Domain Family Member 3 (TSC22D3) and PPARG Coactivator 1 Beta (PPARGC1B) in IS (n=5) and IR+T2DM (n=18) using IS differentiated adipocytes as a control group (C). Adipogenic capacity (lipidtox positive/total number of cells) of expanded preadipocytes in T2DM treated with metformin (n=5) or a combination of metformin and insulin (n=5) (D). Data are presented as Mean±SEM. Differences between groups were tested by ANOVA followed by independent sample *t*-test between IS and all IR (IR+T2DM) groups, \*P\<0.05.Fig. 1.

3.2. Insulin resistance-associated 4-HNE staining, adipocyte size and macrophages infiltration within OM adipose tissues {#s0060}
------------------------------------------------------------------------------------------------------------------------

A semi-quantitative immunohistochemical analysis of adipose tissues from randomly selected samples revealed that disease progression was associated with increased 4-HNE levels in adipocytes ([Fig. 2](#f0010){ref-type="fig"}A), smaller size of the adipocytes ([Fig. 2](#f0010){ref-type="fig"}B) and reduced macrophage infiltration ([Fig. 2](#f0010){ref-type="fig"}C). However, a lower 4-HNE-immunopositivity was detected in OM tissues from metformin and insulin treated T2DM patients when compared to those treated with metformin monotherapy ([Fig. 2](#f0010){ref-type="fig"}D). In the metformin monotherapy group, the 4-HNE immunopositivity was most pronounced in the cellular membranes of the adipocytes (brown color) and occasionally in inflammatory cells infiltrating the adipose tissue, as indicated by arrows ([Fig. 2](#f0010){ref-type="fig"}D top left image). Furthermore, high 4-HNE immunopositivity was also detected in the walls of blood vessels and in the perivascular interstitial connective tissue as indicated by arrows ([Fig. 2](#f0010){ref-type="fig"}D top right image). Only a weak immunopositivity for 4-HNE was seen in the metformin and insulin group in the membranes of some adipocytes and the blood vessel walls, while 4-HNE was mostly absent in their OM interstitial connective tissue (indicated by arrow) as visualized by the blue color of the hematoxylin contrast ([Fig. 2](#f0010){ref-type="fig"}D bottom left image). Furthermore, lower levels of 4-HNE immunopositivity were usually discontinuously present in the membranes of the adipocytes and the interstitial blood vessels in this group (indicated by arrow) ([Fig. 2](#f0010){ref-type="fig"}D bottom right image).Fig. 24-HNE staining, adipocyte size and macrophage infiltration in OM adipose tissue from IS, IR and T2DM patients. 4-HNE immunohistochemical staining (A), adipocyte size (B) and prevalence of infiltrating macrophages (C) within OM adipose tissues (n=17, 3IS, 6IR and 8 T2DM with 4 on metformin and 4 on metformin/insulin) were semi-quantified by an experience pathologist without prior knowledge of the experimental groups. Representative images showing 4-HNE staining (indicated by arrows) in OM tissues from T2DM patients treated with metformin monotherapy (top) or metformin/insulin combined therapy (bottom) (D).Fig. 2.

3.3. Effect of 4-HNE and metformin treatment *in vitro* on ROS production and OM adipogenesis in the presence of insulin {#s0065}
------------------------------------------------------------------------------------------------------------------------

Preadipocytes were treated with metformin, 4-HNE or their combinations in the presence or absence of insulin ([Fig. 3](#f0015){ref-type="fig"}A). Both 4-HNE and metformin treatments caused significant elevation in ROS production in the absence or presence of insulin ([Fig. 3](#f0015){ref-type="fig"}B). Furthermore, 4-HNE, metformin given alone or combined with 4-HNE caused reduced adipogenic capacity that was partially rescued by co-treatment with insulin ([Fig. 3](#f0015){ref-type="fig"}A, C). The lipidtox signal in cells treated with insulin and 4-HNE in the presence of metformin was lower than when metformin was omitted ([Fig. 3](#f0015){ref-type="fig"}A) as quantified in [Fig. 3](#f0015){ref-type="fig"}C. This is probably due to inhibition of adipogenic capacity in response to metformin, despite partial rescue due to presence of insulin. The reduced adipogenic capacity with 4-HNE treatment had no effect on cell size, whilst metformin treatment decreased the size of differentiated cells significantly ([Fig. 3](#f0015){ref-type="fig"}D). Interestingly, 4-HNE treatment caused a significant increase in cell number (p\<0.05), a trend that was also seen in cells treated with metformin and insulin but did not reach statistical significance (p=0.06) ([Fig. 3](#f0015){ref-type="fig"}E).Fig. 3The effect of 4-HNE, metformin and insulin treatment on ROS production and OM adipogenesis. Preadipocytes were treated with 10 µM 4-HNE, 1 mM metformin or their combination in the presence or absence of 0.1 μM human insulin repeatedly for the entire differentiation and maintenance periods. Representative images showing impaired adipogenesis (differentiated adipocytes stained with lipidtox appear in green) in cells treated with 4-HNE and metformin and the partial rescue in the presence of insulin (×100) (A), together with ROS production (B), adipogenic capacity (C), adipocyte size (D) and cell number (E). Data are presented as Mean±SEM (n=6). Differences in paired groups were tested by paired samples Test (UT: untreated control, Ins: Insulin, Met: Metformin). P\<0.05.Fig. 3.

4. Discussion {#s0070}
=============

The intra-abdominal OM adipose tissue has unique anatomic and metabolic characteristics compared to adipose tissues at other locations [@bib36]. Dysfunction of this depot is marked by ectopic fat accumulation and is often associated with hyperinsulinemia and increased risk of T2DM [@bib37], [@bib38]. Our data report for the first time impairment of the adipogenic capacity of OM preadipocytes taken from obese and morbidly obese IR individuals (including T2DM patients) compared to their IS counterparts, with a potential role of 4-HNE accumulation in this impairment. OM preadipocytes of the IS individuals maintained their capacity to differentiate, potentially allowing superfluous triacylglycerols from the sub-cutaneous depot to be stored within the OM depot, therefore reducing ectopic fat accumulation. This is also supported by better liver function parameters of IS patients reported previously [@bib5]. Our data also show evidence that T2DM patients who were already treated with combined metformin and insulin show improved *in vitro* adipogenesis compared to those treated with metformin only. This partial rescue of adipogenesis in the combined therapy group was associated with less infiltration of macrophages and 4-HNE accumulation in their OM adipose tissues. Despite no significant differences in circulating TAGs between the two groups, the therapeutic relevance of improved adipogenesis requires verification in a larger cohort.

Insulin resistance-associated impairment of OM adipogenesis was marked by elevated expression of the anti-adipogenic genes CCND1, FABP4 and TSC22D3, all shown previously to reduce PPARG-mediated adipogenesis [@bib39], [@bib40], [@bib41], and down-regulation of the pro-adipogenic gene PPARGC1B that lays downstream of PPARG [@bib42]. Impaired adipogenesis was also associated with higher macrophage accumulation and 4-HNE staining within the adipose tissues ([Fig. 2](#f0010){ref-type="fig"}). Indeed both macrophages and adipocytes are known to promote inflammation and alter cellular redox homeostasis. Mutual interplay between macrophage oxidative burst and ROS derived from adipocyte metabolism of excess nutrients can trigger lipid peroxidation of readily oxidizable adipocyte lipids yielding formation of 4-HNE [@bib9]. As obesity and T2DM are associated with dyslipidemia, 4-HNE may be generated from organs or tissues other than adipose tissues and spread through the blood. This is consistent with the observations in [Fig. 2](#f0010){ref-type="fig"}D where high 4-HNE staining was primarily detected in the walls of blood vessels and in the perivascular interstitial tissues. It is likely that 4-HNE is transported while bound to proteins such as albumin since 4-HNE-protein adducts are less easily metabolized than free aldehydes that have high affinity to bind to proteins. In favor of this assumption are also findings of increased levels of 4-HNE-protein adducts in the blood of obese men [@bib15]. Thus, acting as systemic mediator of lipid peroxidation 4-HNE might modulate cell growth, differentiation, apoptosis and paly a role as signaling molecule by its direct action and indirect effect caused by modification of proteins [@bib11]. Moreover, 4-HNE was shown to regulate adipose tissue function and differentiation in both mature and in differentiating adipocytes [@bib13]. Still, the pathophysiological roles of oxidative stress, in particular whether 4-HNE is responsible for insulin resistance, remains to be elucidated [@bib43].

In the current study, T2DM-associated impairment of OM adipogenesis was also associated with increased prevalence of small adipocytes, a finding that was previously attributed to adipocyte hyperplasia associated with greater degree of insulin resistance and T2DM [@bib44]. Possible causative/mechanistic involvement of 4-HNE in such pathophysiology of T2DM-associated impairment of OM adipogenesis is strongly supported by increased levels of 4-HNE observed by immunohistochemical analysis of the OM tissue of these patients ([Fig. 2](#f0010){ref-type="fig"}) together with enhanced proliferation and reduced differentiation (adipogenesis) of cultured pre-adipocytes treated with 4-HNE ([Fig. 3](#f0015){ref-type="fig"}). This particular product of lipid peroxidation is well known to enhance proliferation and regulate metabolic stress-response and differentiation as it acts as a growth factor for various types of cells [@bib45], [@bib46], [@bib47], [@bib48].

Furthermore, the finding of increased ROS production in response to 4-HNE treatment *in vitro* indicates that 4-HNE might play crucial role in the onset of the vicious etio-pathogenic circle of obesity, inflammation, oxidative stress and T2DM, which should be further studied to better understand metabolic syndrome and develop improved preventive and therapeutic protocols.

Both metformin and insulin are prescribed therapy protocols for T2DM patients [@bib49]. The synergistic action of insulin with metformin was shown to improve glycemic control over insulin monotherapy [@bib23]. In this study, we hypothesized that the previously reported anti-adipogenic effect of metformin could be rescued with co-treatment with insulin. Indeed, the emerging data suggest rescued adipogenesis in the combined therapy group which is marked by lower circulating IL-6 levels and reduced 4-HNE modified proteins concentrations and macrophage infiltration within the adipose tissues. Differences in the adipogenic capacity between the metformin monotherapy and the combination therapy groups may represent a reflection of imprinted memory on the adipose tissue due to exposure to different medications and their various effects on tissue physiology [@bib5]. The superior adipogenesis of combined treatment was further confirmed by treating cells from IR individuals with metformin in the presence of insulin. The 4-HNE treatment reduced adipogenesis, also reported previously [@bib6], [@bib13], [@bib21], however this phenotype was rescued in the presence of insulin. Furthermore, 4-HNE and metformin significantly induced intracellular adipocyte ROS production *in vitro* while this effect was also partially blunted by insulin. A similar finding was previously reported in 3T3L1 mouse preadipocytes cell line where treatment with metformin increased ROS production while the combination of metformin and insulin did not [@bib50]. The anti-inflammatory role of insulin [@bib51] in the combined treatment group, manifested by lower circulating IL-6, reduced macrophage infiltration within the adipose tissue and the subsequent lower 4-HNE accumulation and ROS production, may have contributed to improved adipogenesis in these patients although the exact mechanism remains to be investigated. Indeed, the anti-adipogenic roles of IL-6 and 4-HNE in sub-cutaneous tissues from insulin resistance and T2DM were recently suggested [@bib5], [@bib6] and the emerging data may suggest a similar role in OM preadipocytes. [Fig. 4](#f0020){ref-type="fig"} represents proposed action of the combined treatment on OM adipogenesis through blunting inflammation and 4-HNE accumulation, as suggested by emerging and recently published data [@bib6].Fig. 4A scheme representing a proposed mechanism for the anti-adipogenic effect of metformin compared to pro-adipogenic effect of combined metformin and insulin therapy highlighting the roles of oxidative stress (ROS), macrophages (MF) and inflammation.Fig. 4.

5. Conclusions {#s0075}
==============

Our results demonstrate insulin-resistance associated impairment of OM adipogenesis and provide a proof of concept that the impaired preadipocyte differentiation and altered cellular redox homeostasis in T2DM patients may be reversible by the synergistic action of insulin and metformin, potentially allowing for a better storage of excess triacylglycerols that otherwise would be deposited ectopically. The involvement of 4-HNE as a potential pathogenic factor and a possible biomarker of impairment of OM adipogenesis in the IR and T2DM patients seems consistent with the recognized role of 4-HNE as a clinical biomarker of different diseases [@bib52], [@bib53]. Studies are needed to evaluate these possibilities and explore the underlying pathophysiological mechanisms based on inflammation and oxidative stress.
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